Drug assessment at a glance: A26-35[1]

Elinzanetant (vasomotor symptoms associated with breast cancer treatment)

17 September 2026

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A26-35. The G-BA decides on the added benefit.

Research question for the benefit assessment

Population	Patients with moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy for breast cancer
Intervention	elinzanetant
Comparator	Watchful waiting
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects

	Size of the effects		Informative value of the effects	
Mortality	∅		–	
Morbidity	∅		–	
Symptoms	∅		–	
Health-related quality of life	∅		–	
Side effects	∅		–	
	∅	No (suitable) data	–	Not applicable
	↔	No advantage or disadvantage	★	Low
	↑ / ↓	Small advantage/disadvantage	★★	Moderate
	↑↑ / ↓↓	Moderate advantage/disadvantage	★★★	High
	↑↑↑ / ↓↓↓	Large advantage/disadvantage		

Overall: no advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects

- No suitable data were available. The OASIS-4 study was not suitable for deriving conclusions on the added benefit of elinzanetant versus the appropriate comparator therapy, as the study phase relevant to the benefit assessment—which compared elinzanetant with placebo—lasted only 12 weeks.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Elinzanetant (vasomotorische Symptome bei Brustkrebsbehandlung); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 01.07.2026]. URL: https://doi.org/10.60584/A26-35.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Elinzanetant (Vasomotorische Symptome, mit Mammakarzinom assoziiert) [online]. 2026 [Accessed: 01.10.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1331/.

English translations for this project are published at https://www.iqwig.de/en/projects/a26-35.html.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de